IL213210A - History of arylcyclopropylacetamide as glucosinase activators - Google Patents

History of arylcyclopropylacetamide as glucosinase activators

Info

Publication number
IL213210A
IL213210A IL213210A IL21321011A IL213210A IL 213210 A IL213210 A IL 213210A IL 213210 A IL213210 A IL 213210A IL 21321011 A IL21321011 A IL 21321011A IL 213210 A IL213210 A IL 213210A
Authority
IL
Israel
Prior art keywords
derivatives useful
glucokinase activators
arylcyclopropylacetamide
arylcyclopropylacetamide derivatives
glucokinase
Prior art date
Application number
IL213210A
Other languages
English (en)
Hebrew (he)
Other versions
IL213210A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL213210A0 publication Critical patent/IL213210A0/en
Publication of IL213210A publication Critical patent/IL213210A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL213210A 2008-12-19 2011-05-30 History of arylcyclopropylacetamide as glucosinase activators IL213210A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380341 2008-12-19
US15378109P 2009-02-19 2009-02-19
PCT/US2009/067603 WO2010080333A1 (en) 2008-12-19 2009-12-11 Arylcyclopropylacetamide derivatives useful as glucokinase activators

Publications (2)

Publication Number Publication Date
IL213210A0 IL213210A0 (en) 2011-07-31
IL213210A true IL213210A (en) 2015-03-31

Family

ID=40545955

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213210A IL213210A (en) 2008-12-19 2011-05-30 History of arylcyclopropylacetamide as glucosinase activators

Country Status (34)

Country Link
US (1) US8063079B2 (cg-RX-API-DMAC10.html)
EP (1) EP2379517B1 (cg-RX-API-DMAC10.html)
JP (1) JP5497064B2 (cg-RX-API-DMAC10.html)
KR (1) KR101290437B1 (cg-RX-API-DMAC10.html)
CN (1) CN102256952B (cg-RX-API-DMAC10.html)
AR (1) AR074470A1 (cg-RX-API-DMAC10.html)
AU (1) AU2009335931B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0923183B1 (cg-RX-API-DMAC10.html)
CA (1) CA2746746C (cg-RX-API-DMAC10.html)
CO (1) CO6382120A2 (cg-RX-API-DMAC10.html)
CR (1) CR20110342A (cg-RX-API-DMAC10.html)
DK (1) DK2379517T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2011000197A (cg-RX-API-DMAC10.html)
EA (1) EA019055B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP11011150A (cg-RX-API-DMAC10.html)
ES (1) ES2435242T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20130983T1 (cg-RX-API-DMAC10.html)
IL (1) IL213210A (cg-RX-API-DMAC10.html)
JO (1) JO2979B1 (cg-RX-API-DMAC10.html)
MA (1) MA32902B1 (cg-RX-API-DMAC10.html)
MX (1) MX2011006434A (cg-RX-API-DMAC10.html)
MY (1) MY180567A (cg-RX-API-DMAC10.html)
NZ (1) NZ592930A (cg-RX-API-DMAC10.html)
PA (1) PA8851901A1 (cg-RX-API-DMAC10.html)
PE (1) PE20120339A1 (cg-RX-API-DMAC10.html)
PL (1) PL2379517T3 (cg-RX-API-DMAC10.html)
PT (1) PT2379517E (cg-RX-API-DMAC10.html)
SG (1) SG172256A1 (cg-RX-API-DMAC10.html)
SI (1) SI2379517T1 (cg-RX-API-DMAC10.html)
TN (1) TN2011000294A1 (cg-RX-API-DMAC10.html)
TW (1) TWI395748B (cg-RX-API-DMAC10.html)
UA (1) UA104742C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010080333A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201103944B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800498C (en) 2010-03-31 2021-11-16 The Scripps Research Institute Reprogramming cells
WO2015075942A1 (ja) * 2013-11-22 2015-05-28 国立大学法人 東京大学 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282612B1 (en) 2000-05-03 2004-12-29 F. Hoffmann-La Roche Ag Alkynyl phenyl heteroaromatic glucokinase activators
BR0110704A (pt) 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
MXPA02010795A (es) 2000-05-08 2003-03-27 Hoffmann La Roche Activadores de glucocinasa de fenilamida sustituida por para-amino.
MY141521A (en) * 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2004076420A1 (ja) * 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
EA012204B1 (ru) 2004-04-21 2009-08-28 Прозидион Лимитед Три(цикло)замещённые амидные соединения
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
AU2005311269B2 (en) * 2004-12-03 2011-11-10 Transtech Pharma, Inc. Heteroaromatic glucokinase activators
BRPI0612582A2 (pt) 2005-07-01 2010-11-23 Novartis Ag combinação de compostos orgánicos
RU2420525C2 (ru) 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
WO2007017649A1 (en) * 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
CA2626475A1 (en) 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP2009514836A (ja) 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
JP2009544648A (ja) * 2006-07-24 2009-12-17 エフ.ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化剤としてのピラゾール類
WO2008084872A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation ヒドラゾン誘導体
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物

Also Published As

Publication number Publication date
UA104742C2 (uk) 2014-03-11
EP2379517A1 (en) 2011-10-26
CR20110342A (es) 2011-09-14
EA201170845A1 (ru) 2011-12-30
BRPI0923183A8 (pt) 2017-09-12
KR101290437B1 (ko) 2013-07-29
EP2379517B1 (en) 2013-08-28
US8063079B2 (en) 2011-11-22
CN102256952B (zh) 2013-12-11
BRPI0923183A2 (pt) 2016-02-16
CA2746746C (en) 2013-09-24
DOP2011000197A (es) 2011-09-15
ES2435242T3 (es) 2013-12-17
ECSP11011150A (es) 2011-07-29
TWI395748B (zh) 2013-05-11
JP2012512874A (ja) 2012-06-07
PE20120339A1 (es) 2012-04-16
MY180567A (en) 2020-12-02
PL2379517T3 (pl) 2014-01-31
KR20110086751A (ko) 2011-07-29
ZA201103944B (en) 2012-11-28
WO2010080333A1 (en) 2010-07-15
US20100160395A1 (en) 2010-06-24
EA019055B1 (ru) 2013-12-30
BRPI0923183B1 (pt) 2019-03-19
HRP20130983T1 (hr) 2013-11-22
TW201029999A (en) 2010-08-16
MX2011006434A (es) 2011-07-19
AU2009335931B2 (en) 2012-05-31
MA32902B1 (fr) 2011-12-01
AU2009335931A1 (en) 2011-07-07
NZ592930A (en) 2013-01-25
DK2379517T3 (da) 2013-09-30
SG172256A1 (en) 2011-07-28
IL213210A0 (en) 2011-07-31
PA8851901A1 (es) 2010-07-27
AR074470A1 (es) 2011-01-19
TN2011000294A1 (en) 2012-12-17
CO6382120A2 (es) 2012-02-15
JP5497064B2 (ja) 2014-05-21
CA2746746A1 (en) 2010-07-15
SI2379517T1 (sl) 2013-10-30
CN102256952A (zh) 2011-11-23
PT2379517E (pt) 2013-11-21
JO2979B1 (en) 2016-03-15

Similar Documents

Publication Publication Date Title
IL209062A0 (en) Glucokinase activators
ZA201006822B (en) Glucokinase activators
IL204746A0 (en) Pyridine derivatives useful as glucokinase activators
IL207099A0 (en) 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of-??-secretase (bace)
ZA201006159B (en) Pyrrolidinone glucokinase activators
IL210855A0 (en) Novel adenine derivatives
EP2185570A4 (en) NOVEL GLUCCOKINASE ACTIVATORS
IL210548A (en) History of spiroamino dihydraziazine
PL2308877T3 (pl) Pochodne imidazopirydyn-2-onu
IL208203A0 (en) Heterocyclic derivatives
IL210406A0 (en) Pyrrolopyridinylpyrimidin - 2 - ylamine derivatives
IL208336A0 (en) Pyrisazinone derivatives
IL210869A0 (en) Imidazothiadiazoles derivatives
PT2367815E (pt) Derivados de piridazinona
IL210613A0 (en) Novel acylaminobenzamide derivatives
IL213424A0 (en) Quinazolinamide derivatives
IL207192A0 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
IL207191A0 (en) Substituted heteroaylamide oxazepyrimidone derivatives
IL208548A0 (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
GB0921210D0 (en) Novel heterocyclic derivatives
IL213210A0 (en) Arylcyclopropylacetamide derivatives useful as glucokinase activators
IL213051A0 (en) Difluorophenyldiacylhydrazide derivatives
HK1157319A (en) Glucokinase activators
GB0821711D0 (en) Dihydroindolone derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed